BMRN Q3 2020 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$477M+3.4% YoY

Gross Profit

$288M60.4% margin

Operating Income

-$56M-11.7% margin

Net Income

$785M164.6% margin

EPS (Diluted)

$4.01

QoQ Revenue Growth

+11.0%

Cash Flow

Operating Cash Flow

$86M

Free Cash Flow

$70M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$6.2B

Total Liabilities

$2.1B

Stockholders' Equity

$4.1B

Cash & Equivalents

$1.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$477M	$461M	+3.4%
Gross Profit	$288M	$364M	-20.9%
Operating Income	-$56M	$4M	-1495.0%
Net Income	$785M	$55M	+1326.0%

Revenue Segments

Royalty And Other

$16M100%

Geographic Segments

UNITED STATES

$253M53%

Europe

$121M25%

Rest Of World

$59M12%

Latin America

$44M9%